Sponsors / VOR
VOR

Vor Biopharma

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
3Trials in this database
9Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)NCT05306574Vor BiopharmaPhase 3Terminated2025-01-06Actual
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)NCT06456580Vor BiopharmaPhase 3Recruiting2027-05Estimated
Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseaseNCT07404865Vor BiopharmaPhase 3Recruiting2028-12Estimated

Latest recorded trial changes

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

NCT05306574 · Vor Biopharma

· 5 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

350 participants (planned)

+ After

91 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

2 Jan 2027

+ After

6 Jan 2025

Recruitment status changed

− Before

Active not recruiting

+ After

Terminated

Check registry source